Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 8/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15444671 | 0.88 | HTR3A (0.61) | HTR3AKCNH2SPRRXFP1POLB | |
| SCHEMBL15420903 | 0.86 | HTR3A (0.58) | HTR3ASPRPOLBGAATSHR | |
| SCHEMBL15441071 | 0.84 | HTR3A (0.59) | HTR3AKCNH2SPRPOLBGAA | |
| SCHEMBL19346266 | 0.82 | HTR3A (0.57) | HTR3AKCNH2POLB | |
| SCHEMBL20080348 | 0.77 | KMT2A (0.52) | HTR3APOLBTSHRKMT2A | |
| SCHEMBL15420794 | 0.73 | HTR3A (1.00) | HTR3A | |
| SCHEMBL15420793 | 0.73 | HTR3A (1.00) | HTR3A | |
| SCHEMBL19970010 | 0.72 | HTR3A (0.56) | HTR3AKCNH2KMT2A | |
| SCHEMBL19969991 | 0.71 | HTR3A (0.56) | HTR3AKCNH2KMT2A | |
| SCHEMBL15444713 | 0.71 | HTR3A (0.60) | HTR3AKCNH2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407443-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407443-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | HTR3A 1/4885KCNH2 1139/4885SPR 1598/4885 |
| US-20170260201-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | HTR3A 1/4885KCNH2 1139/4885SPR 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.